Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Raw Materials (2022 - 2025)

Axsome Therapeutics' Raw Materials history spans 4 years, with the latest figure at $10.4 million for Q4 2025.

  • For Q4 2025, Raw Materials rose 8.76% year-over-year to $10.4 million; the TTM value through Dec 2025 reached $10.4 million, up 8.76%, while the annual FY2025 figure was $10.4 million, 8.76% up from the prior year.
  • Raw Materials for Q4 2025 was $10.4 million at Axsome Therapeutics, down from $12.4 million in the prior quarter.
  • Across five years, Raw Materials topped out at $12.4 million in Q3 2025 and bottomed at $2.1 million in Q3 2022.
  • The 4-year median for Raw Materials is $6.7 million (2024), against an average of $7.1 million.
  • The largest annual shift saw Raw Materials skyrocketed 123.78% in 2023 before it grew 8.76% in 2025.
  • A 4-year view of Raw Materials shows it stood at $2.5 million in 2022, then skyrocketed by 123.78% to $5.5 million in 2023, then surged by 72.41% to $9.5 million in 2024, then increased by 8.76% to $10.4 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Raw Materials are $10.4 million (Q4 2025), $12.4 million (Q3 2025), and $11.7 million (Q2 2025).